Pentraxin 3: A novel biomarker for predicting progression from prostatic inflammation to prostate cancer

Cancer Research

Volumn 74, Issue 16, 2014, Pages 4230-4238

  Stallone, Giovanni ^a   Cormio, Luigi ^a   Netti, Giuseppe Stefano ^a   Infante, Barbara ^a   Selvaggio, Oscar ^a   Di Fino, Giuseppe ^a   Ranieri, Elena ^a   Bruno, Francesca ^a   Prattichizzo, Clelia ^a   Sanguedolce, Francesca ^a   Tortorella, Simona ^a   Bufo, Pantaleo ^a   Grandaliano, Giuseppe ^a   Carrieri, Giuseppe ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PENTRAXIN 3; SERUM AMYLOID P; TUMOR MARKER;

AGED; BLOOD; CONFOCAL MICROSCOPY; DISEASE COURSE; HUMAN; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; PROSTATE; PROSTATE TUMOR; PROSTATITIS;

AGED; C-REACTIVE PROTEIN; DISEASE PROGRESSION; HUMANS; MALE; MICROSCOPY, CONFOCAL; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS; PROSTATITIS; SERUM AMYLOID P-COMPONENT; TUMOR MARKERS, BIOLOGICAL;

EID: 84905992414     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0369     Document Type: Article

References (27)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics 2010. CA Cancer J Clin 2010;60:277-300.
2. Serag H, Banerjee S, Saeb-Parsy K, Irving S, Wright K. Risk profiles of prostate cancers identified from UK primary care using national referral guidelines. Br J Cancer 2012;106:436-9.
3. Zaytoun OM, Kattan MW, Moussa AS, Li J, Yu C, Jones JS. Development of improved nomogram for prediction of outcome of initial prostate biopsy using readily available clinical information. Urology 2011;78:392-8.
4. Presti JC Jr. Repeat prostate biopsy - when, where, how. Urol Oncol 2009;27:312-4.
5. Jiang X, Zhu S, Feng G, Zhang Z, Li C, Li H, et al. Is an initial saturation prostate biopsy scheme better than an extended scheme for detection of prostate cancer? A systematic review and meta-analysis. Eur Urol 2013;63:1031-9.
6. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. (Pubitemid 36859473)
7. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al.: Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-1202.
8. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-69. (Pubitemid 46486616)
9. Caruso C, Balistreri CR, Candore G, Carruba G, Colonna-Romano G, Di Bona D, et al. Polymorphisms of proinflammatory genes and prostate cancer risk: a pharmacogenomic approach. Cancer Immunol Immunother 2009;58:1919-33.
10. Klein EA, Silverman R. Inflammation, infection and prostate cancer. Curr Opin Urol 2008;18:315-9.
11. high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol 2006;177:7398-7405.
12. + regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 2007;13:6947-58.
13. Sfanos KS, Bruno TC, Maris CH, Xu L, Thoburn CJ, DeMarzo AM, et al. Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res 2008;14:3254-61.
14. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-66. (Pubitemid 40563173)
15. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102:636-41. (Pubitemid 30640663)
16. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez de la Torre Y, et al. The long pentraxin PTX3 in vascular pathology. Vasc Pharmacol 2006;45:326-30. (Pubitemid 44765293)
17. Baruah P, Dumitriu IE, Peri G, Russo V, Mantovani A, Manfredi AA, et al. The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol 2006;80:87-95. (Pubitemid 44835529)
18. Rutkowski MJ, Sughrue ME, Kane AJ, Mills SA, Parsa AT. Cancer and the Complement Cascade. Mol Cancer Res 2010;8:1453-65.
19. Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am J Epidemiol 2010;171:571-82.
20. Diamandis EP, Goodglick L, Planque C, Thornquist MD. Pentraxin-3 Is a Novel Biomarker of Lung Carcinoma. Clin Cancer Res 2011;17:2395-9.
21. Tafani M, Di Vito M, Frati A, Pellegrini L, De Santis E, Sette G, et al. Proinflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. J Neuroinflamm 2011;32:1-16.
22. Cormio L, Pagliarulo V, Lorusso F, Selvaggio O, Perrone A, Sanguedolce F, et al. Combined perianal-intrarectal (PI) lidocaine-prilocaine (LP) cream and lidocaine-ketorolac gel provide better pain relief than combined PI LP cream and periprostatic nerve block during transrectal prostate biopsy. BJU Int 2012;109:1776-80.
23. Cormio L, Lorusso F, Selvaggio O, Perrone A, Sanguedolce F, Pagliarulo V, et al. Non-infiltrative anesthesia for transrectal prostate biopsy: a randomized prospective study comparing lidocaine-prilocaine cream and lidocaine-ketorolac gel. Urol Oncol 2013;31:68-73.
24. Irani J, Levillian P, Gouion JM, Bon D, Dore B, Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol 1997;157:1301-3. (Pubitemid 27130803)
25. Willeke F, Assad A, Findeisen P, Schromm E, Grobholz R, von Gerstenbergk B, et al. Overexpression of amember of the pentraxin family (PTX3) in human soft tissue liposarcoma. Eur J Cancer 2006;42:2639-46. (Pubitemid 44442954)
26. Baruah P, Propato A, Dumitriu IE, Rovere-Querini P, Russo V, Fontana R, et al. The pattern recognition receptor PTX3 is recruited at the synapse between dying and dendritic cells, and edits the cross-presentation of self, viral, and tumour antigens. Blood 2006;107:151-8. (Pubitemid 43053537)
27. Ravenna L, Sale P, Di Vito M, Russo A, Salvatori L, Tafani M, et al. Up-regulation of the inflammatory-reparative phenotype in human prostate carcinoma. Prostate 2009;69:1245-55.